SPRUCE BIOSCIENCES INC (SPRB) Stock News

Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder

On Tuesday, Spruce Biosciences, Inc. (NASDAQ:SPRB) revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Congenital adrenal hyperplasia (CAH) is a genetic disease that affects the adrenal glands and prevents the production of hormones like cortisol, aldosterone, and androgens. Also Read: Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disord

Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder

Spruce Biosciences discontinues tildacerfont trials for CAH as CAHmelia-204 misses primary endpoint and CAHptain-205 shows dose-dependent trends.

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024

SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spruce Biosciences (NASDAQ:SPRB) just reported results for the second quarter o...

Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA

Spruce Biosciences Recognized as a Bay Area Best Place to Work

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024

SPRB stock results show that Spruce Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spruce Biosciences (NASDAQ:SPRB) just reported results for the first quarter of...

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such...

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such...

Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Is Altria Giving Up on Anheuser-Busch (BUD) Stock?

Anheuser-Busch stock is falling on Thursday following news that 10% holder Altria is selling a portion of its stake in BUD shares.

Why Is Fisker (FSR) Stock Down 41% Today?

Fisker stock is falling hard on Thursday as FSR investors react to reports that the EV company is preparing to file for bankruptcy.

Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?

Spruce Biosciences stock is falling hard on Thursday as investors in SPRB shares react to the latest clinical trial data reported.